drugset / Trial / NCT02110342

A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body

NCT02110342

Phase 1 Completed 6 enrolled Pfizer
NaSingle-groupOpen-labelBasic science

Summary

The study aims to understand, using radiolabelled PF-04449913, how this compound is modified by the body once it is absorbed. The study also aims to understand how much of the compound is broken down and how much leaves the body unchanged.

Timeline

Start
2014-05
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Glasdegib Small molecule 100 mg Oral
Subject Glasdegib Small molecule 100 unknown Oral

Indications

No indication recorded.